E.g., 05/23/2018
E.g., 05/23/2018

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

05 April, 2018

Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).

AMR Declaration

15 November, 2017

Declaration by the In Vitro Diagnostics Industry on Tackling Antimicrobial Resistance – signed by Mr Belingard, Chairman of bioMérieux November 2017 

2015 UK Product Lists

15 June, 2015

bioMérieux Industry announces the release of UK and Ireland Product Lists

BioFire Receives FDA Clearance for the FilmArray® 2.0 System

26 February, 2015

New system delivers higher throughput, single database management and minimized footprint

Pioneering Diagnostics